Maina is a partner with Sofinnova Partners. Maina joined the firm in 2018 and has a long track record as a successful healthcare investor. Prior to joining Sofinnova Partners, she was Director of Healthcare Investment at Touchstone Innovations (formerly Imperial Innovations) in London (UK), where she led or co-led investments in the UK. Previously, she worked in the R&D teams of several UK and US biotech companies, including Celltech, Oxford Glyco Sciences, Chimeric Therapies and GeneMedicine. Maina holds a BS from the University of Texas at Austin and an MBA from the Imperial Business School. Maina’s current investments include Sitryx Therapeutics, Cincor, and Enyo Pharma.